Compare Global X Copper Miners ETF (COPX) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Novavax Inc — how do they compare? Global X Copper Miners ETF trades at $89.28, while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Global X Copper Miners ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| COPX | NVAX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $11.19 |
52-Week Low | $46.08 | $6.22 |
Market Cap | — | $1.31B |
Enterprise Value | — | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX, the Global X Copper Miners ETF, trades at $88.03, up 2.25% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF provides exposure to copper mining equities, which are leveraged to copper demand from AI data centers and electrification trends. Recent news highlights institutional accumulation and a buying opportunity after a pullback from 2026 highs.
The outlook is positive due to structural copper demand growth, though mining equities have underperformed copper futures year-to-date. Risks include commodity price volatility and supply bottlenecks. Analyst sentiment is bullish, emphasizing COPX as a pick-and-shovel play on AI infrastructure.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
